Topic: siRNA

Saloni Dattani and Jacob Trefethen discuss siRNA medicines that suppress production of harmful proteins without changing DNA. They examine the long path from discovery to treatment, why existing drugs concentrate on liver diseases, programmable and long-lasting effects, and prospects and limitations for treating infection, cardiovascular disease, rare disorders and cancer.

Temporal lobe epilepsy (TLE), the most common form of DRE, is associated with enhanced glutamate receptor-mediated hyperexcitability in the temporal lobe structures. The mechanism of regulation of aberrant glutamatergic activity in TLE is still elusive. Sema 3F regulates the AMPA receptor surface expression in post-synapse. In this study, we investigated the contribution of semaphorin3F (SEMA 3F) to glutamatergic synaptic activity in TLE rats' hippocampus and anterior temporal lobe (ATL). synaptic transmission in the hippocampus and ATL. Golgi-Cox staining was conducted to visualize alteration

Parkinson’s disease (PD) is a debilitating neurodegenerative disorder and there is no cure to treat or prevent the disease. The cardinal motor symptoms of PD are caused by a decline of nerve cells producing the neurotransmitter dopamine, which is necessary for the initiation of voluntary movements, but other transmitter systems including the serotonin and norepinephrine systems are affected as well and are related to non-motor symptoms such as depression and dementia. On a pathological level, PD is also characterized by intracellular proteinaceous inclusions known as Lewy bodies that contain t